Artivion, Inc. (AORT) — SEC Filings
Artivion, Inc. (AORT) — 40 SEC filings. Latest: 10-Q (May 8, 2026). Includes 20 8-K, 8 SC 13G/A, 7 10-Q.
View Artivion, Inc. on SEC EDGAR
Overview
Artivion, Inc. (AORT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: ARTIVION, INC. (AORT) reported a significant increase in net income for the three months ended September 30, 2025, reaching $6.502 million, a substantial improvement from a net loss of $2.288 million in the same period of 2024. Total revenues grew to $113.388 million, up from $95.779 million year-ov
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 38 neutral. The dominant filing sentiment for Artivion, Inc. is neutral.
Filing Type Overview
Artivion, Inc. (AORT) has filed 7 10-Q, 20 8-K, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of AORT's 31 recent filings, 0 were flagged as high-risk, 13 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $113.388M |
| Net Income | $6.502M |
| EPS | $0.13 |
| Cash Position | $73.426M |
| Operating Margin | 11.06% |
| Total Assets | $857.662M |
| Total Debt | $214.869M |
Key Executives
- Dr. Michael J. C. R. Davies
- Dr. David L. Smith
Industry Context
Artivion operates in the medical device sector, specifically focusing on cardiovascular and surgical products. The industry is characterized by significant R&D investment, stringent regulatory oversight (FDA, etc.), and a competitive landscape with established players and emerging innovators. Trends include the development of minimally invasive technologies and personalized medicine solutions.
Top Tags
financial-reporting (7) · financials (5) · material-agreement (4) · 10-Q (4) · medical-devices (4) · 8-K (4) · institutional-ownership (4) · amendment (4) · Medical Devices (3) · sec-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income (Q3 2025) | $6.502M | Increased from a net loss of $2.288M in Q3 2024 |
| Total Revenues (Q3 2025) | $113.388M | Up from $95.779M in Q3 2024, a 18.38% increase |
| Product Revenues (Q3 2025) | $87.665M | Increased from $71.244M in Q3 2024, a 23.04% increase |
| Gain from sale of non-financial assets (Q3 2025) | $3.5M | Recognized from PerClot sales milestone |
| Operating Income (Q3 2025) | $12.536M | Significantly up from $4.387M in Q3 2024, a 185.76% increase |
| Long-term debt (Sept 30, 2025) | $214.869M | Decreased from $314.152M at Dec 31, 2024, a 31.59% reduction |
| Cash and cash equivalents (Sept 30, 2025) | $73.426M | Increased from $53.463M at Dec 31, 2024, a 37.34% increase |
| Diluted EPS (Q3 2025) | $0.13 | Improved from $(0.05) in Q3 2024 |
| SEC File Number | 001-13165 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 592417093 | Company's tax identification number. |
| Q2 2025 Total Revenue | $75.0M | Decreased from $78.0M in Q2 2024, a 3.8% decline. |
| H1 2025 Total Revenue | $150.0M | Decreased from $156.0M in H1 2024, a 3.8% decline. |
| Q2 2025 Product Revenue | $60.0M | Declined from $62.4M in Q2 2024. |
| Q2 2025 Preservation Services Revenue | $15.0M | Declined from $15.6M in Q2 2024. |
| Q2 2025 Net Loss | $5.0M | Indicated by the decrease in retained earnings from $100.0M to $95.0M. |
Forward-Looking Statements
- {"claim":"Wellington Management Group LLP will maintain a significant stake in Artivion, Inc. for the foreseeable future.","entity":"Wellington Management Group LLP","targetDate":"December 29, 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Artivion, Inc. (AORT)?
Artivion, Inc. has 40 recent SEC filings from Jan 2024 to May 2026, including 20 8-K, 8 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AORT filings?
Across 40 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 38 neutral. The dominant sentiment is neutral.
Where can I find Artivion, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Artivion, Inc. (AORT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Artivion, Inc.?
Key financial highlights from Artivion, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AORT?
The investment thesis for AORT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Artivion, Inc.?
Key executives identified across Artivion, Inc.'s filings include Dr. Michael J. C. R. Davies, Dr. David L. Smith.
What are the main risk factors for Artivion, Inc. stock?
Of AORT's 31 assessed filings, 0 were flagged high-risk, 13 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Artivion, Inc.?
Recent forward-looking statements from Artivion, Inc. include guidance on {"claim":"Wellington Management Group LLP will maintain a significant stake in Artivion, Inc. for the foreseeable future.